methylphenidate has been researched along with Parkinson Disease, Secondary in 3 studies
Methylphenidate: A central nervous system stimulant used most commonly in the treatment of ATTENTION DEFICIT DISORDER in children and for NARCOLEPSY. Its mechanisms appear to be similar to those of DEXTROAMPHETAMINE. The d-isomer of this drug is referred to as DEXMETHYLPHENIDATE HYDROCHLORIDE.
methylphenidate : A racemate comprising equimolar amounts of the two threo isomers of methyl phenyl(piperidin-2-yl)acetate. A central stimulant and indirect-acting sympathomimetic, is used (generally as the hydrochloride salt) in the treatment of hyperactivity disorders in children and for the treatment of narcolepsy.
methyl phenyl(piperidin-2-yl)acetate : A amino acid ester that is methyl phenylacetate in which one of the hydrogens alpha to the carbonyl group is replaced by a piperidin-2-yl group.
Parkinson Disease, Secondary: Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The causes of nigrostriatal neuron degeneration in Parkinson's disease (PD) are not known, but it has been suggested that exogenous or endogenous factors or neurotoxins may play a role." | 1.33 | An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: antiparkinson effects of Sinemet and protective effects of methylphenidate. ( Delville, Y; Fleming, SM; Schallert, T, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cucarián, JD | 1 |
| Berrío, JP | 1 |
| Rodrigues, C | 1 |
| Zancan, M | 1 |
| Wink, MR | 1 |
| de Oliveira, A | 1 |
| Cepeda, MS | 1 |
| Kern, DM | 1 |
| Seabrook, GR | 1 |
| Lovestone, S | 1 |
| Fleming, SM | 1 |
| Delville, Y | 1 |
| Schallert, T | 1 |
1 trial available for methylphenidate and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Comprehensive Real-World Assessment of Marketed Medications to Guide Parkinson's Drug Discovery.
Topics: Adrenergic beta-Antagonists; Adult; Antiparkinson Agents; Cohort Studies; Databases, Factual; Drug D | 2019 |
2 other studies available for methylphenidate and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Physical exercise and human adipose-derived mesenchymal stem cells ameliorate motor disturbances in a male rat model of Parkinson's disease.
Topics: Animals; Dopaminergic Neurons; Humans; Male; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem | 2019 |
An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: antiparkinson effects of Sinemet and protective effects of methylphenidate.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Carbidopa; Cell Count; Differential Threshold; Dise | 2005 |